Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EOC202 with Albumin-bound Paclitaxel in HR+/HER2- Advanced Breast Cancer
NCT05322720Phase 2Unknown
- Sponsor
- EOC Pharma
- Start
- Apr 2022
- Primary completion
- Mar 2023
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Fc-Fusion Proteins
01
Overview
Phase 2, randomised, open-label trial of eftilagimod alpha in breast cancer (2 arms), sponsored by EOC Pharma. Primary endpoint: Progression-Free Survival up to 30 months. Status: unknown.
02
Drugs
eftilagimod alpha
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05322720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05322720.